IL6 and COVID-19: Studies have shown that adding tocilizumab to standard COVID-19 treatment regimens significantly reduces mortality rates and the need for hospitalization or ventilation.361–363 The diverse therapeutic applications of these IL-6 inhibitors underscore the potential of targeting gp130/IL-6 signaling as a broad strategy for managing inflammatory diseases.